Cytek Biosciences, Inc. CTKB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s cash & equivalents?
- Cytek Biosciences, Inc. (CTKB) reported cash & equivalents of $31.81M in Q1 2026.
- How has Cytek Biosciences, Inc.'s cash & equivalents changed year-over-year?
- Cytek Biosciences, Inc.'s cash & equivalents decreased by 66.6% year-over-year, from $95.3M to $31.81M.
- What is the long-term trend for Cytek Biosciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s cash & equivalents has grown at a -29.4% compound annual growth rate (CAGR), from $165.23M to $28.98M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.